GLP-1 & Weight Management
GLP-1 receptor agonists and metabolic therapies for weight management, metabolic health, and appetite regulation. Includes semaglutide, tirzepatide, and related compounds.
Retatrutide
Retatrutide (LY3437943)
A triple-agonist peptide (GIP/GLP-1/Glucagon receptor) showing the most dramatic weight loss results in clinical trials — up to 24% body weight reduction. Also showing anti-aging effects beyond weight loss.
Tirzepatide
Tirzepatide (Mounjaro/Zepbound)
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. Demonstrates significant weight loss and metabolic improvements in large clinical trials.
Semaglutide
Semaglutide (Ozempic/Wegovy)
The most well-known GLP-1 receptor agonist, approved for both diabetes and obesity. Backed by extensive clinical data and the largest user base of any weight loss medication.
Cagrilintide
Cagrilintide (CagriSema)
A long-acting amylin analog being studied in combination with semaglutide (CagriSema). Early results suggest enhanced weight loss beyond semaglutide alone.